The impact of dapagliflozin on  HbA 1c  , systolic blood pressure and weight: a review of dapagliflozin use in a Scottish city | Zendy

Kueh Christopher JL | Zendy; Connelly Paul | Zendy; Harte Rachael | Zendy; Smith Christopher | Zendy; Boyle James G | Zendy

Premium

The impact of dapagliflozin on HbA 1c , systolic blood pressure and weight: a review of dapagliflozin use in a Scottish city

Author(s) -

Kueh Christopher JL,

Connelly Paul,

Harte Rachael,

Smith Christopher,

Boyle James G

Publication year - 2017

Publication title -

practical diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.205

H-Index - 24

eISSN - 2047-2900

pISSN - 2047-2897

DOI - 10.1002/pdi.2100

Subject(s) - dapagliflozin , medicine , blood pressure , diabetes mellitus , type 2 diabetes , urinary system , population , cohort , urology , endocrinology , environmental health

We aimed to determine the efficacy of dapagliflozin in the management of type 2 diabetes in a Scottish population through measurements of glycaemic control, blood pressure and weight. Dapagliflozin was effective in improving HbA 1c by 10 mmol/mol ( SE 1.8, p < 0.001), systolic blood pressure by 9. 8mmHg ( SE 2.2, p < 0.001) and weight by 3.2 kg ( SE 0.6, p < 0.001). There was a significant proportion of people with diabetes who reported side effects with dapagliflozin relating to genital and urinary tract infections. Dapagliflozin appears to be an effective drug in improving HbA 1c , systolic blood pressure and weight in people with type 2 diabetes. However, in this cohort a substantial proportion of people with diabetes did not tolerate this drug due to side effects. Copyright © 2017 John Wiley & Sons.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research